562 related articles for article (PubMed ID: 10385219)
1. The long-lasting effect of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion in dogs.
Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
J Pharm Pharmacol; 1999 Apr; 51(4):457-64. PubMed ID: 10385219
[TBL] [Abstract][Full Text] [Related]
2. Effects of TU-199, a novel H+, K(+)-ATPase inhibitor, on gastric acid secretion and gastroduodenal ulcers in rats.
Uchiyama K; Wakatsuki D; Kakinoki B; Takeuchi Y; Araki T; Morinaka Y
Methods Find Exp Clin Pharmacol; 1999 Mar; 21(2):115-22. PubMed ID: 10327392
[TBL] [Abstract][Full Text] [Related]
3. Effects of IY-81149, a newly developed proton pump inhibitor, on gastric acid secretion in vitro and in vivo.
Kwon D; Chae JB; Park CW; Kim YS; Lee SM; Kim EJ; Huh IH; Kim DY; Cho KD
Arzneimittelforschung; 2001; 51(3):204-13. PubMed ID: 11304936
[TBL] [Abstract][Full Text] [Related]
4. A study comparing the antisecretory effect of TAK-438, a novel potassium-competitive acid blocker, with lansoprazole in animals.
Hori Y; Matsukawa J; Takeuchi T; Nishida H; Kajino M; Inatomi N
J Pharmacol Exp Ther; 2011 Jun; 337(3):797-804. PubMed ID: 21411494
[TBL] [Abstract][Full Text] [Related]
5. Differences in the antisecretory actions of the proton pump inhibitor AG-1749 (lansoprazole) and the histamine H2-receptor antagonist famotidine in rats and dogs.
Nagaya H; Inatomi N; Satoh H
Jpn J Pharmacol; 1991 Apr; 55(4):425-36. PubMed ID: 1886288
[TBL] [Abstract][Full Text] [Related]
6. Biochemical and pharmacological properties of a newly synthesized proton pump (H+/K(+)-ATPase) inhibitor, TY-11345 in experimental animals.
Yamaguchi T; Aihara K; Yamada S; Narita S; Kogi K
Jpn J Pharmacol; 1993 Aug; 62(4):363-71. PubMed ID: 8230863
[TBL] [Abstract][Full Text] [Related]
7. Effect of four lansoprazole dose levels and one dosage regimen of omeprazole on 24-hour intragastric pH in healthy subjects.
Timmer W; Ripke H; Kleist P; Ehrlich A; Wieckhorst G; Lücker PW; Fuder H
Methods Find Exp Clin Pharmacol; 1995 Sep; 17(7):489-95. PubMed ID: 8577212
[TBL] [Abstract][Full Text] [Related]
8. General pharmacological properties of the new proton pump inhibitor (+/-)-5-methoxy-2-[[(4-methoxy-3,5-dimethylpyrid-2-yl)methyl]sulf inyl]- 1H-imidazo[4,5-b]pyridine.
Kakinoki B; Ono C; Yamazaki N; Chikamatsu N; Wakatsuki D; Uchiyama K; Morinaka Y
Methods Find Exp Clin Pharmacol; 1999 Apr; 21(3):179-87. PubMed ID: 10389120
[TBL] [Abstract][Full Text] [Related]
9. Effects of the enantiomers of lansoprazole (AG-1749) on (H+ + K+)-ATPase activity in canine gastric microsomes and acid formation in isolated canine parietal cells.
Nagaya H; Inatomi N; Nohara A; Satoh H
Biochem Pharmacol; 1991 Oct; 42(10):1875-8. PubMed ID: 1660270
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological characteristics of 3-butyryl-8-methoxy-4-[(2-thiophenyl)amino]quinoline, a new proton-pump inhibitor, in rabbit gastric microsomes and in rats.
Kim KB; Chang MS; Chung YK; Sohn SK; Kim SG; Choi WS
J Pharm Pharmacol; 1998 May; 50(5):521-9. PubMed ID: 9643446
[TBL] [Abstract][Full Text] [Related]
11. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y
J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418
[TBL] [Abstract][Full Text] [Related]
12. 1-[5-(2-Fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438), a novel and potent potassium-competitive acid blocker for the treatment of acid-related diseases.
Hori Y; Imanishi A; Matsukawa J; Tsukimi Y; Nishida H; Arikawa Y; Hirase K; Kajino M; Inatomi N
J Pharmacol Exp Ther; 2010 Oct; 335(1):231-8. PubMed ID: 20624992
[TBL] [Abstract][Full Text] [Related]
13. Characteristics of the K+-competitive H+,K+-ATPase inhibitor AZD0865 in isolated rat gastric glands.
Kirchhoff P; Andersson K; Socrates T; Sidani S; Kosiek O; Geibel JP
Am J Physiol Gastrointest Liver Physiol; 2006 Nov; 291(5):G838-43. PubMed ID: 16798725
[TBL] [Abstract][Full Text] [Related]
14. Gastric antisecretory activity of lansoprazole in different experimental models: comparison with omeprazole.
Coruzzi G; Adami M; Bertaccini G
Gen Pharmacol; 1995 Sep; 26(5):1027-32. PubMed ID: 7557245
[TBL] [Abstract][Full Text] [Related]
15. Properties of the reversible, K(+)-competitive inhibitor of the gastric (H+/K+)-ATPase, SK&F 97574. II. Pharmacological properties.
Parsons ME; Rushant B; Rasmussen TC; Leach C; Ife RJ; Postius S; Pope AJ
Biochem Pharmacol; 1995 Nov; 50(10):1551-6. PubMed ID: 7503756
[TBL] [Abstract][Full Text] [Related]
16. Antisecretory and antiulcer effect of T-330, a novel reversible proton pump inhibitor, in rats.
Kinoshita M; Saito N; Tamaki H
Eur J Pharmacol; 1997 Mar; 321(3):325-32. PubMed ID: 9085044
[TBL] [Abstract][Full Text] [Related]
17. Current status of acid pump antagonists (reversible PPIs).
Wurst W; Hartmann M
Yale J Biol Med; 1996; 69(3):233-43. PubMed ID: 9165692
[TBL] [Abstract][Full Text] [Related]
18. The comparative effects of lansoprazole, omeprazole, and ranitidine in suppressing gastric acid secretion.
Blum RA; Shi H; Karol MD; Greski-Rose PA; Hunt RH
Clin Ther; 1997; 19(5):1013-23. PubMed ID: 9385488
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the inhibitory activity of tenatoprazole on the gastric H+,K+ -ATPase in vitro and in vivo.
Shin JM; Homerin M; Domagala F; Ficheux H; Sachs G
Biochem Pharmacol; 2006 Mar; 71(6):837-49. PubMed ID: 16405921
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the effect of lansoprazole in suppressing acid secretion using 24-hour intragastric pH monitoring.
Takeda H; Hokari K; Asaka M
J Clin Gastroenterol; 1995; 20 Suppl 1():S7-9. PubMed ID: 7673616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
